Helius Medical Technologies Inc Class A

NASDAQ HSDT

Download Data

Helius Medical Technologies Inc Class A Interest Expense To Sales 1 year YoY Change (%) for the quarter ending March 31, 2024: -119.66%

Helius Medical Technologies Inc Class A Interest Expense To Sales 1 year YoY Change (%) is -119.66% for the quarter ending March 31, 2024, a -117.66% change year over year. The interest expense to sales ratio is a financial metric that represents the proportion of a company's revenue that is used to cover its interest expenses. It is calculated by dividing the company's interest expense by its total revenue. This ratio indicates the financial burden of interest payments on the company's operating income. A higher ratio suggests that a significant portion of the company's revenue is being used to service interest obligations, potentially affecting its profitability. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Helius Medical Technologies Inc Class A Interest Expense To Sales for the quarter ending March 31, 2023 was 90.09%, a -21.48% change year over year.
  • Helius Medical Technologies Inc Class A Interest Expense To Sales for the quarter ending March 31, 2022 was 114.74%, a -30.66% change year over year.
  • Helius Medical Technologies Inc Class A Interest Expense To Sales for the quarter ending March 31, 2021 was 165.48%, a -54.63% change year over year.
  • Helius Medical Technologies Inc Class A Interest Expense To Sales for the quarter ending March 31, 2020 was 364.73%, a -69.68% change year over year.
NASDAQ: HSDT

Helius Medical Technologies Inc Class A

CEO Mr. Dane Carl Andreeff
IPO Date June 27, 2014
Location United States
Headquarters 642 Newtown Yardley Road, Newtown, PA, United States, 18940
Employees 22
Sector Healthcare
Industry Medical devices
Description

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. Helius Medical Technologies, Inc. was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

StockViz Staff

September 20, 2024

Any question? Send us an email